Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Sciences 
Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer




[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development



[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Monsenso partners with Australian Mental & Social Health Counselling Service Provider On the Line

Monsenso partners with Australian Mental & Social Health Counselling Service Provider On the Line

Monsenso will partner with On the Line to assist counsellors in helping clients self-manage their anxiety, bipolar disorder, borderline personality disorder, depression, post-traumatic stress disorder and schizophrenia.

Copenhagen, Denmark – 19 December 2017 Monsenso, a Danish company developing mobile health solutions for mental health has partnered with On the Line, an Australian social health business. On the Line offers telephone, web chat and video counselling and social media moderation services 24/7 to more than 80, 000 people each year.

Monsenso’s mHealth solution will act as a proactive self-management app to strengthen the support and connection between counsellors and clients with a wide range of affective  and psychotic disorders. Specifically, the solution will offer a detailed routine monitoring system to help On the Line counsellors access detailed information regarding clients. This information will help counsellors  to support clients to better manage their health.

Clients will be able to input mood level, hours slept, medication taken, exercise, stress and more and this data will be fed into the dashboard to give On the Line counsellors a historic overview and analysis for each client.

“Our mHealth solution is the ideal complement to remote  and outpatient care.” said Thomas Lethenborg, CEO of Monsenso, “The live-time data collection and synchronization between clinician and client can help to enhance the quality of psychotherapeutic counselling.”  

On the Line has more than 55 years of experience in delivering mental health services to the community. It is the national provider of some of Australia’s most vital and trusted services, including MensLine AustraliaSuicide Call Back Service and SuicideLine Victoria. On the Line helps encourage people to feel better by building resilience, fostering healthy relationships, and connecting people with community support.

“The Monsenso solution will help counsellors to have a clearer picture of how their clients feel on a daily basis. For our clients, it will help them to manage their condition, identify triggers and warning signs and empower them to better manage their social health and wellbeing.” said Kim O’Neill, CEO at On The Line.

Click on this link to read this press release in Danish.

For additional information contact:

Helen Chen
+45 30 25 15 26

Monsenso partners with Gen Re to bring mHealth solution to insurance

Monsenso partners with Gen Re to bring mHealth solution to insurance

Copenhagen, Denmark – 19 April 2017. Monsenso, a Copenhagen-based technology company developing mHealth solutions for mental health, today announced a partnership with Gen Re, one of the world’s leading reinsurance companies. The objective of the partnership is to help insurance companies take advantage of Monsenso’s mHealth solution, which can assist in the prevention, early intervention and treatment of mental illness.

The Monsenso mHealth solution provides practical care to people with behavioural disorders, and has the potential to improve the prevention and management of disability claims.

Patient surveys reveal that mHealth technology increases an individual’s desire to play a more active role in their treatment. With the Monsenso mHealth solution, individuals can self-monitor their lifestyle and their symptoms, helping them recover faster from mental illness.

Gen Re delivers reinsurance solutions to the Life/Health and Property/Casualty insurance industries. With $14 billion in capital and approx. $6 billion in premiums, it is one of the leading reinsurers in the world with a global network of offices in key reinsurance markets.

Gen Re and Monsenso will work together to help insurance companies offer an enhanced service to their customers, and reduce costs in the process. By offering the solution, insurers can actively help their customers return to work more quickly, and avoid becoming ill again

Thomas Lethenborg, CEO at Monsenso, said, “The objective of this partnership is to promote the use of mHealth technology among insurance companies.  With this technology, their customers can get better faster by receiving better mental health care, while reducing costs at the same time.”

“Monsenso is looking to build sustainable, long-term partnerships, with the ultimate goal of delivering better care, to more people, at a lower cost,” added Mr. Lethenborg.

With a desire to bring the best innovative new technology solutions to their clients, Gen Re bring their extensive insurance industry knowledge to the partnership.

Jules Constantinou, Regional Manager, Gen Re Life/Health UK & Ireland, said, “ It is important that the life insurance industry embrace new technologies and new processes in order to remain relevant in the lives of customers going forward. Clinical medicine is also evolving and we are very pleased to announce this partnership with Monsenso, which should improve outcomes for insurance claimants who are battling mental illness”.

“We anticipate working closely with Monsenso to find solutions for Gen Re’s insurance clients and their customers worldwide” added Mr. Constantinou.

With its origins at the IT University of Copenhagen, the Monsenso mHealth solution for mental illnesses holds a CE Mark. It is currently being used in a clinical capacity in the UK, Denmark, Norway, Sweden, Germany and Australia to support the treatment of a wide range of mental and behavioural disorders.


For additional information contact:
Jennifer Highland
Marketing and Communications Manager
+45 81 75 80 01

Ross Campbell
Chief Underwriter
Life/Health Research & Development
Gen Re, UK
+ 44 (0)207 426 1803

About Gen Re
Gen Re delivers reinsurance solutions to the Life/Health and Property/Casualty insurance industries. We work closely with our clients to understand their strategic and operational goals, offering a wide range of products, tools and resources that aim to promote our clients’ ongoing growth and success. As a direct reinsurer, we are in the risk assumption business, just like our clients. Our shared perspective helps us understand and evaluate even the toughest risks – and propose the right solutions. Gen Re is a member of the Berkshire Hathaway family of companies, and has earned superior financial strength ratings from each of the major rating agencies.  To learn more visit: